|
Register for PCF Virtual 21st Anniversary Pharmaceutical and Medical Device Compliance Congress by Friday 10/2 for Early Bird; New Discounted Rates Available
|
- Virtual Online Video Event Live and 6 Months Access to Video Archive
- Sponsored by the Pharmaceutical Compliance Forum
- Media Partners: Harvard Health Policy Review, Health Affairs and Life Sciences Compliance Update
- November 4 - 6, 2020
- www.PharmaCongress.com
PRESS RELEASE
Phone: 800-503-7419
Email: reginfo@hcconferences.com
Website: www.PharmaCongress.com
|
NEW EARLY BIRD REGISTRATION
DATE: FRIDAY 10/2
|
Early bird registration discounts now available through Friday 10/2 with special PCF rates. Rates are up to $1,000 less than major competing events.
- Click here to register.
|
|
NEW DISCOUNTED RATES NOW AVAILABLE
|
STANDARD RATES:
|
CONFERENCE - STANDARD
INDIVIDUAL REGISTRATION:
|
-- Through Friday, October 2, 2020* |
$1,895
|
-- After Friday, October 2, 2020 |
$2,295
|
|
STANDARD GROUP REGISTRATION DISCOUNT:
|
-- 3 or more |
$1,695
|
-- 6 or more |
$1,495
|
-- 9 or more |
$1,295
|
|
|
PHARMACEUTICAL COMPLIANCE FORUM (PCF) RATES:
|
SPECIAL PHARMACEUTICAL COMPLIANCE
FORUM (PCF) RATES**:
|
-- Through Friday, October 2, 2020* |
$1,195
|
-- After Friday, October 2, 2020 |
$1,595
|
|
PCF GROUP REGISTRATION DISCOUNTS:
|
-- 3 or more |
$995
|
-- 6 or more |
$795
|
-- 9 or more |
$595
|
|
|
AGENDA AT-A-GLANCE
(sessions subject to change)
|
|
CONCURRENT CCO ROUNDTABLE AND MINI SUMMITS I & II
INVITATION-ONLY, CLOSED CCO ROUNTABLE (10 am EST - 12:15 pm EST)
|
10:00 am |
Welcome & Introductions
|
10:10 am |
OIG Presentation on Technology (Big Data, Analytics and AI) and Compliance
|
10:40 am |
AdvaMed & PhRMA Reports
|
11:00 am |
DOJ Presentation on High Risk Compliance Issues related to Speaker Programs
|
11:30 am |
Facilitated, Interactive Discussion Video Roundtables on Promotional Programs (Up to 20 each; pre-assigned)
|
12:00 pm |
Reports from Discussion Roundtables
|
12:15 pm |
Adjournment
|
|
MINI SUMMITS I & II
|
|
MINI SUMMITS I (10 am EST - 11 am EST)
|
|
- I: Building Ethics and Integrity into your Compliance Program
- II: Practices in Operationalizing Speaker Programs
- III: State Price Transparency and Reporting Requirements
- IV: Operationalizing Updates to the Sunshine Law
|
|
MINI SUMMITS II (11 am EST - 12:15 pm EST)
|
|
- V: Third Party Management Beyond Due Diligence: Selecting, Integrating and Managing Third Parties throughout the Relationship Lifecycle
- VI: Fraud and Abuse Risks Related to COVID-19 Relief
- VII: Annual Medical Device Roundtable
- VIII: Navigating Interactions AND Compliance Concerns with HCPs during a Pandemic
|
|
OPTIONAL LIVE INTERACTIVE TOPIC DISCUSSIONS
(12:15 pm EST - 1:00 pm EST)
(Open to all; May move among sessions.)
|
|
OPENING PLENARY SESSION (1 pm EST - 5 pm EST)
|
1:00 pm |
Welcome and Introduction: PCF Co-Chairs
|
1:15 pm |
Keynote: OIG Update by Mary Riordan
|
2:00 pm |
US DOJ Keynote
|
3:15 pm |
FDA Keynote
|
3:45 pm |
Annual Chief Compliance Officer Fireside Chat
|
5:00 pm |
Adjournment
|
THURSDAY, NOVEMBER 5, 2020
|
|
CONCURRENT MINI SUMMITS III & IV
MINI SUMMITS III (10 am EST - 11 am EST)
|
|
- IX: Compliance Considerations for Rare and Ultra Rare Drugs
- X: Best Practices of Conducting Investigations
- XI: Compliance Monitoring in a Virtual World
- XII: Compliance Challenges Posed by Small Organizations
- XIII: Managing Monitorships to Maximize Effectiveness
- XIV: Patient Services Compliance Survey (Year 4) Update
|
|
MINI SUMMITS IV (11:15 am EST - 12:15 pm EST)
|
|
- XV: Enforcement Actions on Fraud and Misuse of Patient Support Programs
- XVI: Compliance Risk Assessment Alignment to Enterprise Risk Management
- XVII: Reflections on a Successful Co-Promotion Partnership
- XVIII: Government Enforcement Trends
- XIX: FDA Regulatory Updates for Compliance Professionals
- XX: SEC Compliance: Living in the Material (Non-Public Information) World
|
|
OPTIONAL LIVE INTERACTIVE TOPIC DISCUSSIONS (12:15 pm EST - 1:00 pm EST)
(Open to all; May move among sessions.)
|
|
PLENARY SESSION (1 pm EST - 5 pm EST)
|
1:00 pm |
Welcome and Introduction: PCF Co-Chairs
|
1:15 pm |
COVID-19 and Vaccine Development Update
|
1:45 pm |
Equity, Diversity and Inclusion Keynote Address
|
2:15 pm |
Implementing, Equity, Diversity, and Inclusion Roundtable
|
3:15 pm |
US DOJ and US SEC Update on FCPA Enforcement
|
4:15 pm |
Advanced Patient Engagement Strategies
|
5:00 pm |
Adjournment
|
|
CONCURRENT MINI SUMMITS V & VI
|
|
MINI SUMMITS V (10 am EST - 11 am EST)
|
|
- XXI: Social Media Communication, Including Promotion of Products Across Borders
- XXII: Risk Management for Interactions with Specialty Pharmacies
- XXIII: Privacy, GDPR and California Consumer Privacy Act - What's Next
- XXIV: DOJ's Fundamental Question: "Does the Corporation's Compliance Program Work" in Practice?
- XXV: Update on Expedited CIA and Key Components
|
|
MINI SUMMITS VI (11:15 am EST - 12:15 pm EST)
|
|
- XXVI: Engagement and Support for Board Oversight of the Compliance Program
- XXVII: Research and Development Compliance Challenges
- XXVIII: Managing Communication Issues during a Crisis or an Emerging Post-crisis Environment
- XXIX: Market Access and Payer Interactions
- XXX: Key Learnings from Enforcement Actions in the Opioid Crisis
|
|
OPTIONAL LIVE INTERACTIVE TOPIC DISCUSSIONS (12:15 pm EST - 1:00 pm EST)
(Open to all; May move among sessions.)
|
|
CLOSING PLENARY SESSION (1 pm EST - 4 pm EST)
|
1:00 pm |
Welcome and Introduction: PCF Co-Chairs
|
1:15 pm |
Roundtable on Implications of the Election for Lifesciences, including Pricing and Cost Containment Policy
|
2:00 pm |
Using Data Analytics and Automation to Drive Smarter, More Effective and Cost-Effective Compliance Programs
|
2:45 pm |
Annual AUSA Roundtable
|
3:00 pm |
The Post-Pandemic Compliance Department of the Future: Virtual, Ethics, Integrity and More
|
4:00 pm |
Adjournment
|
|
|
NETWORK VIA OUR ADVANCED VIRTUAL BROADCAST AND NETWORKING PORTAL
|
|
WASHINGTON, DC USA -- PHARMA UPDATE NEWS SERVICE -- SEPTEMBER 28, 2020: The 21st Anniversary Pharmaceutical and Medical Device Compliance Congress, www.PharmaCongress.com, to be held November 4 - 6, 2020 as a fully virtual event, today announced the conference dates and a call for presentation proposals.
|
CO CHAIRS
|
Indrani Franchini, JD
Executive Vice President Chief Compliance Officer, Alexion Pharmaceuticals, New York, NY
(PCF CO-Chair) |
Jeffrey Kawalek, MBA
Deputy Chief Compliance Officer, Jazz Pharmaceuticals, Inc., Philadelphia, PA
(PCF Chair) |
Margaret Sparks, JD
Associate Vice President, North America Ethics and Business Integrity, Sanofi US, Bridgewater, NJ (PCF Co-chair)
|
Ann Marie Tejcek
Senior Director, Chief Compliance Officer North America, Eli Lilly, Indianapolis, IN
(PCF CO-Chair) |
Donna White, CCEP
Vice President, Contracts & Compliance Chiesi, Cary, NC
(PCF CO-Chair) |
Joe Zimmerman
Vice President, Chief Compliance Officer & Privacy Officer, Ferring Pharmaceuticals, Parsippany, NJ
(PCF Co-chair)
|
|
KEYNOTE SPEAKERS
|
Craig Carpenito, JD
United States Attorney, US Attorney's Office, District of New Jersey; Former Senior Counsel, Northeast Regional Office, US Securities and Exchange Commission; Newark, NJ |
Susan Dentzer
Visiting Fellow, Duke-Margolis Center for Health Policy; Former Editor in Chief, Health Affairs; Former Health Correspondent, PBS NewsHour; Washington, DC |
Robert I. Dodge, JD
Assistant Director, FCPA Unit, US Securities & Exchange Commission; Former Assistant U.S. Attorney, US Attorney's Office, Western District of Michigan; Former Assistant Section Chief, Environmental Defense Section, US Department of Justice; Washington, DC
|
Robert W. Dubois, MD, PhD
Interim President and CEO, National Pharmaceutical Council (NPC); Former Chief Medical Officer, Cerner LifeSciences; Washington, DC |
Gustav W. Eyler, JD
Director, Consumer Protection Branch, Civil Division, US Department of Justice, Washington, DC |
Catherine (Katie) Gray, PharmD
Acting Director, Office of Prescription Drug Promotion (OPDP), US Food and Drug Administration, Silver Spring, MD
|
Matthew J. Lash, JD
Trial Attorney, Consumer Protection Branch, US Department of Justice, Washington, DC |
Andy Mao, JD
Deputy Director, Fraud Section, Civil Division, Elder Justice Initiative Coordinator, US Department of Justice, Washington, DC |
Dan Mendelson, MPP
Founder, Avalere Health, Operating Partner, Welsh, Carson, Anderson & Stowe, Board, Centrexion Therapeutics Corp., Washington, DC
|
Mary E. Riordan, JD
Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services, Washington, DC |
Gregg Shapiro, JD
Assistant US Attorney and Chief, Affirmative Civil Enforcement Unit, US Attorney's Office, District of Massachusetts, US Department of Justice, Boston, MA |
Edie Stringfellow, MS
Director, Diversity & Inclusion, Massachusetts Biotechnology Council, Cambridge, MA
|
|
FEATURING THE ANNUAL INVITATION-ONLY CHIEF COMPLAINCE OFFICER ROUNDTABLE
|
November 4, 2020; Invitation-only; No Cost. CCOs interested in attending may contact Debra Scanlon, Administrator, Pharmaceutical Compliance Forum at info@pharmacomplianceforum.org.
|
|
AdvaMed UPDATE
|
Christopher L. White, JD
Chief Operating Officer & General Counsel, Advanced Medical Technology Association (AdvaMed), Washington, DC
|
|
|
PhRMA UPDATE
|
Julie Ritchie Wagner, JD
Assistant General Counsel, PhRMA; Former Senior Counsel, Office of Counsel to the Inspector General, US DHHS; Washington, DC
|
|
|
OIG ANALYTICS/AI UPDATE
|
Renata Marziarz Miskell, MPA
Senior Advisor to the Chief Data Officer, Inspector General, US Department of Health and Human Services, Washington, DC
|
|
|
DOJ SPEAKER PROGRAMS UPDATE
|
Jake Lillywhite, JD
Assistant US Attorney, Civil Division, US Attorney's Office, Southern District of New York, US Department of Justice, New York, NY
|
|
|
FEATURING THE ANNUAL CHIEF COMPLIANCE OFFICER FIRESIDE CHAT WITH
|
Dennis K. Barnes, JD CPA
Vice President, Global Governance, Risk & Compliance, Mayne Pharma; Former Vice President, Compliance & Risk Management, Global Compliance Officer, PAREXEL International; Raleigh-Durham, NC |
Mark Graves, JD, MBA
Senior Vice President and Chief Compliance Officer, MiMedx; Former Director, Global Patient Experience & Value, UCB; Former Senior Director, Pharmaceutical Products Division, Abbott; Marietta, GA |
Nancy A. Grygiel, JD
Senior Vice President, Chief Compliance Officer, Amgen; Former VP Compliance, Corporate & International, Allergan; Former Senior Director Global Compliance, Mylan; Newbury Park, CA
|
John Knighton, JD
Chief Compliance Officer, TherapeuticsMD; Former Vice President, Head of Global Compliance, Orexigen Therapeutics; Boca Raton, FL |
Tara R. Shewchuk, JD, LLM
Vice President and Deputy, Office of Ethics & Compliance, Medtronic; Former Senior Director, Ethics and Compliance, Abbott (now AbbVie); Former VP, Chief Compliance, Privacy & Security Officer, Resurrection Health Care (now Ascension/AMITA); Minneapolis, MN |
Tom Gregory, MBA
Partner, Forensic & Integrity Services, EY, Atlanta, USA (Moderator)
|
|
AND A ROUNDTABLE ON IMPLEMENTING EQUITY, DIVERSITY AND INCLUSION BY
|
Michael R. Clarke, CCEP
Vice President, Global Chief Compliance Officer, ConvaTec; Former VP, Corporate Compliance, Indivior; Former VP, Ethics & Compliance, Americas, Actavis; Former VP & Compliance Officer, Biomet Spine & Bone Healing Technologies; Bridgewater, NJ |
Sujata Dayal, JD
Vice President & Global Chief Compliance Officer, Medline Industries; Former VP Healthcare Compliance & Privacy, Johnson & Johnson; Former Global Chief Compliance Officer and Corporate VP, Biomet; Chicago, IL |
Jill Fallows Macaluso
Corporate Vice President, Chief Ethics, Compliance & Privacy Officer, NovoNordisk, Princeton, NJ
|
Robert A. Ladd, JD
Vice President, Global Head Integrity & Compliance, Novartis, Oncology; Former General Counsel, GE Healthcare; Former Global Head of Compliance Training, Goldman Sachs; Former Senior Corporate Counsel, Pfizer; New York, NY |
Latarsha Stewart, JD, MS
Vice President, Head of Compliance, Servier Pharmaceuticals; Former Head of Compliance, Global Oncology Business Unit, Takeda Oncology; Boston, MA
|
|
|
|
|
|
FEATURED FACULTY
|
Khelin N. Aiken, JD
Partner, Baker & McKenzie LLP; Former Regulatory Counsel, Center for Drug Evaluation and Research, US Food and Drug Administration (FDA), Washington, DC |
Sergio Alegre, JD
Vice President, Global Compliance, Osmotica; Former Executive Director Compliance, Pacira; Bridgewater, NJ |
John T. Bentivoglio, JD
Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud, and Chief Privacy Officer, US Department of Justice; Washington, DC |
Richard Bistrong, MA
Chief Executive Officer, Front-Line Anti-Bribery LLC, Contributing Editor, FCPA Blog; Former Confidential Human Source (CHS) and Cooperating Witness, FBI and US DOJ; Former Cooperating Witness, City of London Police, HMRC and CPS, UK; New York, NY |
Joseph Calarco
Vice President, Compliance, Nabriva Therapeutics; Former Chief Compliance Officer, NEOS Therapeutics; Former Director, Compliance & Ethics, US Operations, Bristol-Myers Squibb; Lansdale, PA
|
Christie Camelio
Chief Compliance, Ethics & Risk Management Officer, TG Therapeutics; Former Vice President, Deputy Global Chief Compliance Officer, Celgene; New York, NY |
Cynthia Cetani
Chief Integrity & Compliance Officer, Indivior; Former Group Integrity & Compliance, Head, Compliance Operations, Novartis International AG; Richmond, VA |
Katherine Chaurette, MS, JD
Vice President Healthcare Law and Compliance, Blueprint Medicines; Former Sr. Director, Regulatory and Commercial Law, Regeneron; Former VP, Legal, Head of Health Law, Regulatory, Market Access, Marketed and Launch Products, Sanofi; Jamaica Plain, MA |
Masha Chestukhin, MSJ
Associate Director, Compliance Officer R&D, IA, FMV, Sanofi Genzyme; Former Senior Manager NA Compliance, Sanofi; Jamaica Plain, MA |
Yvonne Clark, JD
Corporate Compliance Counsel, Spark Therapeutics; Former Commercial Counsel, Merck; Philadelphia, PA
|
Thomas Costa, JD
Member, US Board of Directors, Sanofi, Former Vice President, US Compliance & Ethics, Bristol-Myers Squibb, Washington, DC |
Clarissa Crain
Senior Manager, Deloitte; Former Analyst, Commercial Operations, Cephalon; Philadelphia, PA |
BJ D'Avella, MBA
Group Leader, Life Sciences Consulting Group, Paul Hastings, New York, NY |
Ethan Davis, JD
Partner, King & Spalding LLP; Former Acting Assistant Attorney General, Civil Division, US Department of Justice; Washington, DC |
Kimberly Davis, JD
Chief Compliance Officer, Kaleo, Richmond, VA
|
Anisa Dhalla
Global Chief Compliance Officer, UCB, Inc.; Former Manager, Regulatory Affairs, Solvay and Mikart; Atlanta, GA |
Sarah diFrancesca, JD
Partner, Dinsmore & Shohl LLP, Cincinnati, OH |
Stefanie A. Doebler, JD
Of Counsel and Co-chair, Health Care Practice Group, Covington & Burling LLP, Washington, DC |
Tara D'Orsi, JD
Executive Vice President, Chief Compliance Officer and General Counsel, Kyowa Kirin North America; Former Senior Counsel, Reliant Pharmaceuticals; New York, NY |
J. Mark Farrar, CPA, CFE, CFF
Managing Director, Navigant, Former Interim Global Chief Compliance Officer, Beckman Coulter, Atlanta, GA
|
Margaret Feltz, MA, JD
Vice President, Ethics & Compliance, Purdue Pharma; Former Compliance Counsel, Boehringer Ingelheim; Stamford, CT |
Christine Fiore, MBA
Executive Director, Ethics and Commercial Compliance, Boehringer Ingelheim; Former Group Director Ethics and Compliance, Smith & Nephew; Ridgefield, CT |
Gary F. Giampetruzzi, Esq.
Partner, Paul Hastings; Former Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc.; New York, NY |
Thomas M. Glavin, JD
Chief Compliance Officer for the Americas, Olympus Corporation of the Americas; Former Vice President, US/Americas Compliance Officer, Shire; Center Valley, PA |
Betania Glorio, LLM
Global Compliance Officer, Healthcare, Merck KGaA; Former Senior Director, Legal and Compliance EMEA, Horizon, Raptor and Onyx; Darmstadt, Germany
|
Gejaa T. Gobena, JD
Partner, Hogan Lovells; Former Deputy Chief, Fraud Section, Criminal Division; Former Trial Attorney, Civil Division, Fraud Section, US Department of Justice; Washington, DC |
Thomas Goimarac, MBA, CHFP
Managing Consultant, Berkeley Research Group, LLC (BRG), Phoenix, AZ |
Christine Gordon, JD
Deputy Chief Compliance Officer, Olympus Corporation of the Americas, Former Assistant District Attorney, Philadelphia District Attorney's Office, Bethlehem, PA |
Adam Greene, JD, MPH
Partner and Co-chair, Health Information & HIPAA Practice, Davis Wright Tremaine LLP; Former Senior Health Information Technology and Privacy Specialist, Office for Civil Rights, HHS; Washington, DC |
Michael Hercz, JD
Senior Vice President and General Counsel, Sentynl; Former Vice President, Law & Chief Compliance Officer, Victory Pharma; Former Executive Director, Enterprise Risk Management, Amgen; Solana Beach, CA
|
Saul B. Helman, MD, MBA
Partner, Life Sciences Functional Practice Leader, Guidehouse, Former Director, Eli Lilly, Zionsville, IN |
Emily Huebener, MA
Senior Manager, Health and Life Sciences Forensic & Integrity Services, EY, Chicago, IL |
Briannon Irwin, JD
Senior Managing Consultant, Berkeley Research Group (BRG); Former Judicial Law Clerk, The Supreme Court of Pennsylvania; Washington, DC |
Michael Joachim, JD
Head of Ethics & Business Integrity, Specialty Care, Sanofi Genzyme, Cambridge, MA |
Marci Juneau, MBA
Partner, Helio Health Group, Atlanta, GA
|
Catherine Healy Kanzler
Executive Director, Global Compliance Operations, Olympus Corporation of the Americas, Center Valley, PA |
Ben Kaye-Smith
Senior Vice President Ethics, Risk & Compliance, AveXis; Former Corporate Health Safety Environment Manager; Former Global Head Integrity & Compliance Risk Review & Prevention, Novartis; Switzerland |
Jonathon L. Kellerman
Executive Vice President, Global Chief Compliance Officer – Advisor, Office of Ethics & Compliance, Allergan Aesthetics, an AbbVie company; Former Executive Vice President, Global Chief Compliance Officer; Allergan, Madison, NJ |
Andrea L. Kocharyan, JD
Vice President, Head of Legal & Compliance, Zealand US; Former VP, Head of Legal Affairs, Sumitomo Dainippon Oncology; Former VP, US General Counsel & Compliance Officer, EVO Biologics; Cambridge, MA |
Keith Korenchuk, MPH, JD
Vice President and Chief Compliance Officer, DH Diagnostics, a Danaher Company, Chevy Chase, MD
|
Kirt Kraeuter, MGA
Senior Director, Corporate Compliance at Moderna; Former European Compliance Director, Otsuka; Former, Executive Director, Worldwide Compliance Committee & Monitoring, Bristol-Myers Squibb; Yardley, PA |
Daryl Kreml, JD
Vice President, Chief Compliance Officer and Investigations Counsel, Sage Therapeutics; Former Head, US Compliance & Global Program Management, Biogen; Former Director & Senior Managing Counsel, Int'l Compliance, Boston Scientific; Cambridge, MA |
Nancy Libin, JD
Partner and Co-Chair, Privacy & Security, and Technology Practice, Davis Wright Tremaine LLP; Former Chief Privacy and Civil Liberties Officer, US Department of Justice; Washington, DC |
Jodi Lindsey, JD
Vice President, Healthcare Counsel and Head of U.S. Compliance, Alkermes; Former Associate Director, Commercial Compliance, Biogen; West Roxbury, MA |
Kari K. Loeser, JD
Senior Corporate Counsel & U.S. Healthcare Compliance Officer, Relypsa, Inc; Former Investigator, U.S. Department of Health & Human Services; Former, Policy Analyst, American Medical Association; Redwood City, CA
|
Joshua Marks, JD
Vice President, Chief Ethics & Compliance Officer, Boehringer Ingelheim; Former Executive Division Counsel, Corporate Compliance Officer & Asst. Secretary, Ben Venue Laboratories; Ridgefield, CT |
Jill Mason, JD
Chief Ethics and Compliance Officer, Orthofix; Former Senior Global Compliance Director, St. Jude Medical; Lewisville, TX |
Jane Mathews, LLM, JD
Vice President and Chief Compliance Officer, Lexicon; Former Assistant General Counsel, Sunovion; Former Senior Counsel-Managing Attorney - Head of Litigation, Hoffmann-La Roche; Ringwood, NJ |
Heather McCollum, JD, MHA, CCEP-I
Director, Compliance, Shionogi, Florham Park, NJ |
Jennifer McGee, JD
Vice President & Chief Compliance Officer, Otsuka America Pharmaceutical, Rockville, MD
|
Kathleen McGovern, JD
Global Investigator, Healthcare & Crisis Management Advisor, EY; Former Senior Deputy Chief, Fraud Section, US Department of Justice; Washington, DC |
Jenny McVey, MS, PHD
Compliance Risk Strategy & Management, Novo Nordisk, Compliance Lead, Hands International, Editorial Board Member, Policy & Medicine Compliance Update, Princeton, NJ |
Vahan Minassian, JD
Director, US Promotional Monitoring Lead, Pfizer, Philadelphia, PA |
Patrick Mooty
Head of Compliance, Sumitomo Dainippon Pharma America, Marlborough, MA |
Gregory S. Moss, LLB
Executive Vice President, General Counsel and Corporate Secretary, Chief Compliance Officer, Kadmon Holdings, New York, NY
|
Kristin Mykulak, JD
Assistant General Counsel, Litigation & Compliance, Dr. Reddy's Laboratories, Princeton, NJ |
Katie Norris, MPA
Director, West Coast Leader, Life Sciences Governance, Risk Management and Compliance, Guidehouse, Former Senior Director, Compliance & Integrity Programs, NSF Health Sciences, San Francisco, CA |
Amy Pawloski
President, Strategic Versatility; Former Global Compliance Operations Officer, Endo; Phoenixville, PA |
Veleka Peeples-Dyer, JD
Partner and Chair, North America Food and Drug, Administration (FDA) Practice Group, Baker & McKenzie LLP, Washington, DC |
Brad Powers, JD
General Counsel and Chief Compliance Officer, Lumos Pharma; Former General Counsel and Chief Compliance Officer, Office of the CEO, NewLink Genetics; Des Moines, IA
|
Ariadna Quesada, MPP, MSJ
Compliance Director International EMEA, Hillrom; Former Ethics and Compliance Officer, The Netherlands, AbbVie; Former Compliance Director International, DaVita Kidney Care; Amsterdam, Netherlands |
Kristin Rand, JD, MA
Head, Corporate Compliance and Global Risk Officer, Moderna; Former Vice President & Chief Compliance Officer, Seattle Genetics; Boston, MA |
Kelly N. "Nikki" Reeves, MPA, JD
Partner and Co-chair, Life Sciences and Healthcare Industry Group, King & Spalding LLP, Washington, DC |
Chapman Richardson
Global Head, Data Consumerization, Sanofi; Former Executive Director, Global Next, Generation Digital, Novartis; Bridgewater NJ |
Kevin Ryan, MS, JD
Vice President, Chief Compliance Officer, ACADIA; Former Director, Ethics & Compliance, Novo Nordisk; San Diego, CA
|
Jennifer Santos, MPH, JD
Head of Global Corporate Compliance Operations, Vertex Pharmaceuticals; Former Associate General Counsel, Tufts Medical Center; Boston, MA |
Jonathan Sayegh, JD
Associate Director, Compliance & Ethics, Sunovion, Marlborough, MA |
Eric Siegel, MBA, JD
Vice President, Head of Compliance US, Idorsia Pharmaceuticals US Inc.; Former Chief Compliance Officer, Jazz Pharmaceuticals; Former Senior Investigator, Office of the Inspector General, City of Philadelphia; Philadelphia, PA |
Paul Silver
Principal, Regulatory & Compliance Life Sciences Leader, Deloitte Advisory, Deloitte, Atlanta, GA |
Melissa Tearney, JD
Partner and Co-chair, Litigation Department, Choate, Hall & Stewart, Boston, MA
|
Bryan Timer, MA
Director, Data Analytics & Transparency, Merck and Co, Inc., Kenilworth, NJ |
Elizabeth Weiss, JD
Assistant General Counsel, Pfizer; Former Research Chemist, Ortho Clinical Diagnostics; Peapack, NJ |
Caroline H. West, JD
Global Chief Compliance Officer, Olympus Corporation; Former Senior Vice President, Chief Compliance and Risk Officer, Shire; Philadelphia, PA |
Seth B. Whitelaw, JD, LLM, SJD
President and Chief Executive Officer, Whitelaw Compliance Group, LLC; Editor, Life Science Compliance Update; Senior Fellow & Adjunct Professor, Life Sciences Compliance, Mitchell Hamline School of Law; West Chester, PA
|
Ron L. Wiser, Jr, JD
Partner, Hogan Lovells, Washington, DC |
Amy Yuda, MSJ, CHC, CQA, CCEP
Compliance Officer, PolarityTE, Salt Lake City, UT
|
|
2020-2021 GLOBAL PHARMA/MED DEVICE ETHICS & COMPLIANCE CONGRESSES
|
|
VIRTUAL TWENTY-FIRST ANNUAL PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS
|
Virtual Online Video Event Live and Archived
Sponsored by Pharmaceutical Compliance Forum
Media Partners: Harvard Health Policy Review, Health Affairs and Policy & Medicine Compliance Update
November 4 - 6, 2020
www.PharmaCongress.com
|
|
VIRTUAL FOURTEENTH INTERNATIONAL PHARMACEUTICAL AND MEDICAL DEVICE ETHICS & COMPLIANCE CONGRESS
|
Virtual Online Video Event Live and Archived
Sponsored by International Society of Healthcare Compliance Professionals (ETHICS)
Media Partner: Policy & Medicine Compliance Update
February 22 - 25, 2021
www.International PharmaCongress.com
|
|
CONGRESS EXHIBIT & SPONSORSHIP INFORMATION
|
For sponsorship and exhibit information contact Suzanne Tyler, Exhibit Manager, at (206) 244-4861 phone, (206) 319-5303 fax, or exhibits@hcconferences.com.
|
|
|
|